Ansun Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Ansun's estimated annual revenue is currently $8.5M per year.(i)
  • Ansun's estimated revenue per employee is $155,000

Employee Data

  • Ansun has 55 Employees.(i)

Ansun's People

NameTitleEmail/Phone
1
CEO & Chairperson Reveal Email/Phone
2
VP Clinical DevelopmentReveal Email/Phone
3
VP CMCReveal Email/Phone
4
Director QualityReveal Email/Phone
5
Associate Director, R&DReveal Email/Phone
6
Project ManagerReveal Email/Phone
7
Senior Human Resources ManagerReveal Email/Phone
8
Sr. Scientist CMC AnalyticalReveal Email/Phone
9
Senior Principal ScientistReveal Email/Phone
10
Senior Regulatory AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Ansun?

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has two products in late stage clinical development. Fludase is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. Paradase is an investigational nebulized drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of lower tract parainfluenza infection in immunocompromised patients.

keywords:N/A

N/A

Total Funding

55

Number of Employees

$8.5M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Ansun News

2022-04-17 - L-Citrulline Market Size, Outlook And Forecast | Nutra Green ...

... Zhaoqing City Dingkang Pharmaceutical, Ansun Bioengineering, Shanghai Join-Ray Biotechnology, MH2 Biochemical, Premium Ingredient.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.4M5541%N/A
#2
$13.4M554%N/A
#3
$7.2M55N/AN/A
#4
$7.2M55N/AN/A
#5
$6.9M55-10%$2M